Desirable Properties of Radiopharmaceuticals for Sentinel Node Mapping in Patients With Breast Cancer Given the Paradigm Shift in Patient Management.
Over the past 2 decades, lymphoscintigraphy and sentinel node biopsy have become widely accepted and are used by surgeons to stage many solid cancers, especially breast cancer. However, despite growing experience, there are a number of unresolved issues. In addition, the impact of a new radiopharmaceutical remains to be determined. The present article addresses some of these issues (either unresolved, recurrent, or newly emerged), with a focus on the properties of radiopharmaceuticals used for sentinel node mapping in breast cancer.
From the *Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; †Departments of Radiology and Medicine, McMaster University, Hamilton, Ontario, Canada.
Chun K
CK
Kim
Katherine A
KA
Zukotynski
D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D061305:Lymphoscintigraphy / Q000379:methods* / Q000592:standards; D010346:Patient Care Management / Q000379:methods / Q000592:standards; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000493:pharmacokinetics / Q000592:standards*; D000071036:Sentinel Lymph Node / Q000000981:diagnostic imaging* / Q000473:pathology
D019275:Radiopharmaceuticals